INS and type 2 diabetes mellitus: Another study comparing the addition of empagliflozin or linagliptin to premixed insulin therapy in T2D patients found that while empagliflozin was associated with a reduction in muscle mass, neither drug caused significant changes in skeletal muscle mass [20].